Taken together, our study suggests that selection of HER2+ breast cancer patients based on the level of pre-existing TILs may be useful and critical for an optimal anti-Her2 mAb-based combination therapy with better therapeutic outcome. The gene discussed is ERBB2; the disease is breast carcinoma.